Paroxetine for hepatopulmonary syndrome?

Medical Hypotheses

Volumn 62, Issue 3, 2004, Pages 446-447

  Altschuler, Eric Lewin ^a,b   Kast, Richard E ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PAROXETINE;

DRUG INDICATION; DRUG SAFETY; HEPATOPULMONARY SYNDROME; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; SHORT SURVEY; VASODILATATION;

EID: 1642325649     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.10.017     Document Type: Article

References (5)

1. Fallon MB, Abrams GA. Hepatopulmonary syndrome. Curr Gastroenterol Rep 2000;2:40-5.
2. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003;37:192-7.
3. Cremona G, Higenbottam TW, Mayoral V, et al. Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J 1995;8:1883-5.
4. Rolla G, Brussino L, Colagrande P, et al. Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med 1998;128:375-8.
5. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996;32:653-8.